Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and...
The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the ...
04:01PM Gilead Sciences Easily Beats Third-Quarter Views Driven By Solid Biktarvy Sales (Investor's Business Daily) 12:26PM Top 20 biopharmas market cap rises 2% in Q3 2024 amid flurry of drug approvals (Pharmaceutical Technology) Nov-05-24 07:19PM Analyst Report: Gilead Sciences, Inc. ...
Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection...
(in number of shares) 80 000 80 000 80 000 80 000 65 000 385 000 385 000 Daily weighted average purchase price of the shares 134,2658 134,5947 135,7952 135,8487 137,7185 135,5638 135,56380 Market (MIC Code) XPAR XPAR XPAR XPAR XPAR Identity code of...
(HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy ...
Your Daily Pharma Scoop: Genocea Surges, Gilead's Biktarvy, GlaxoSmithKline's Vaccine Succeeds In Late-Stage StudyAvisol Capital PartnersWed, Mar. 07, 2018 Genocea Biosciences: 200% Dilution, Hopelessness And Anger. Why Am I Still Holding? GEN-009 And ATLASConfoundedinterestThu, Feb. 01, 2018...